FINNENCE
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE ASSET FILE

PERMANENT ASSET RECORD · TRACKED BY FINNENCE

AZN

AstraZeneca

AZN · EQUITY · IMPORTANCE 0.5

$168.37
LAST CLOSE2026-09-22 · +0.2%

AstraZeneca — 5 stories tracked over the last 30 days. No call on record.

LAST $168.37·Δ1D +0.2%·Δ20D +1.0%·60D RANGE $155.62–$195.15·FROM 60D HIGH -13.7%·RADAR FLAGS 30D 2

SECTION 01 · THE MACHINE'S FILE

WHAT FINNENCE THINKS.

NO CALL ON RECORD

the engine publishes a call only when every gate clears

SEE THE LEDGER →
NOT A MEMBER OF ANY TRACKED THEME

theme membership updates every few hours

ALL THEMES →

RADAR FLAG · Sep 15, 2026

CORRELATION BREAK

SEVERITY 1.0 · Z -0.4 · +4.7%

MACRO

Broad market or volatility move

ON THE RADAR →

SECTION 02 · THE PRICE RECORD

NINETY SESSIONS, ONE LINE.

$168.372026-05-142026-09-22
LAST$168.37Δ1D+0.2%Δ20D+1.0%60D RANGE$155.62–$195.15

INTERACTIVE PRICE — TRADINGVIEW

SECTION 03 · THE STORY FLOW

WHAT THE FEED SAW.

Recent stories
2026-09-20 08:01 UTCNEWSMIXEDSanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss - finance.yahoo.com
2026-09-16 14:41 UTCNEWSMIXEDAstraZeneca shares oversold after trial flops and merger talk, says UBS - Proactive financial news
2026-09-10 14:31 UTCNEWSBULLISHObesity Market Set for Explosive 27% CAGR Growth by 2036, Fueled by 7 Promising Emerging Therapies | DelveInsight
2026-09-04 12:00 UTCCOMPANYUNCLEARFDA approves ETCAMAH — Astrazeneca Pharmaceuticals, Lp
2026-09-01 10:18 UTCNEWSUNCLEARAstraZeneca subsidiary lists €2.55bn bonds on LSE - Investing.com
OPEN THE FEED →

SECTION 04 · CATALYSTS

2027-01-06 12:00 UTCTRIALDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

LATEST PRICES

NO PRICE SAMPLES.

METHODOLOGY · PAPER ONLY

OPEN THE MACHINE →

A permanent, data-backed asset record. Calls are immutable; market data and machine detections update. PAPER ONLY · NOT FINANCIAL ADVICE.

INSPECT THE PAPER FUND →